EGFR and glioma: In addition, Aibaidula et al. specifically examined the adult IDH wild-type lower-grade gliomas, demonstrating significant heterogeneity within this group, with differences in prognosis based on further molecular classification by biomarkers such as TERTp mutation, EGFR amplification, H3F3A mutation, and MYB amplification [1].